EGFR and non-small cell lung carcinoma: In view of the results reported by the IPASS study [1], gefitinib (IRESSA, AstraZeneca Pharmaceuticals, Wilmington, DE, USA) was the first TKI approved by the European Medicines Agency (EMEA) for first-line therapy in adults with locally advanced or metastatic EGFR mutated NSCLC.